Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). June 1, 2026 conference call and webcast covering interim Phase 1 healthy-volunteer results for JADE101.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- June 1, 2026 conference call and webcast covering interim Phase 1 healthy-volunteer results for JADE101
- JADE101 targets APRIL for IgA nephropathy, positioning the program in an important renal-disease development area
- Corporate presentation in Exhibit 99.1 may contain material trial updates and development milestones
- Live webcast available through Jade’s “Events and Presentations” webpage
Item 8.01 · Other Events
- Phase 1 interim data: single JADE101 doses produced approximately 70% IgA reductions sustained 12 weeks at 700 mg
- Potential convenient regimen: simulated greater than 70% IgA reduction with 700 mg induction, then 350 mg every 12 weeks
- Safety favorable through 1,400 mg: no serious adverse events or discontinuations; headache affected 25% and upper respiratory infection 21.9%
- Phase 2 JUNIPER underway in approximately 30 IgAN participants, testing maintenance dosing every 8 or 12 weeks
- Registrational Phase 3 targeted for first half of 2027, pending FDA requirements and confirmation of efficacy and safety in patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.